Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,007 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus.
Su H, Ye X, Freed DC, Li L, Ku Z, Xiong W, Gao P, Liu X, Montgomery D, Xu W, Espeseth AS, Wang D, Ma N, Fu TM, Zhang N, An Z. Su H, et al. Among authors: montgomery d. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e02422-20. doi: 10.1128/AAC.02422-20. Print 2021 Feb 17. Antimicrob Agents Chemother. 2021. PMID: 33361306 Free PMC article.
Assessment of Bezlotoxumab Immunogenicity.
Montgomery DL, Matthews RP, Yee KL, Tobias LM, Dorr MB, Wrishko RE. Montgomery DL, et al. Clin Pharmacol Drug Dev. 2020 Apr;9(3):330-340. doi: 10.1002/cpdd.729. Epub 2019 Aug 14. Clin Pharmacol Drug Dev. 2020. PMID: 31411386
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Aliprantis AO, Wolford D, Caro L, Maas BM, Ma H, Montgomery DL, Sterling LM, Hunt A, Cox KS, Vora KA, Roadcap BA, Railkar RA, Lee AW, Stoch SA, Lai E. Aliprantis AO, et al. Among authors: montgomery dl. Clin Pharmacol Drug Dev. 2021 May;10(5):556-566. doi: 10.1002/cpdd.883. Epub 2020 Oct 30. Clin Pharmacol Drug Dev. 2021. PMID: 33125189 Clinical Trial.
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Khalilieh S, Hussain A, Montgomery D, Levine V, Shaw PM, Bodrug I, Mekokishvili L, Bailey-Smith C, Glasgow XS, Cheng A, Martinho M, Iwamoto M. Khalilieh S, et al. Among authors: montgomery d. Br J Clin Pharmacol. 2018 Oct;84(10):2292-2302. doi: 10.1111/bcp.13670. Epub 2018 Jul 31. Br J Clin Pharmacol. 2018. PMID: 29926968 Free PMC article. Clinical Trial.
1,007 results